Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,870 total articles

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical reported 2025 financial results highlighting significant progress in clinical trials for its Selective Cytopheretic Device (SCD) therapy for Acute Kidney Injury (AKI), expanding the QUELIMMUNE therapy's adoption in top pediatric hospitals, and preparing for FDA approvals. The company achieved over 50% enrollment in the pivotal NEUTR…

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium, a clinical-stage biotech focused on immunobiology therapies for autoimmune and inflammatory diseases, reported Q4 and full year 2025 financial results. The company completed two financings totaling $85 million, bolstering cash reserves to $30.3 million as of year-end plus $35 million raised in March 2026, expected to fund operations thro…

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Inc. announced the FDA acceptance and priority review of its New Drug Application for gedatolisib targeting HR+/HER2-/PIK3CA wild-type advanced breast cancer with a PDUFA date of July 17, 2026. Positive Phase 3 trial results from the PIK3CA WT cohort showed significant improvement in progression-free survival and well-being measures. Topli…

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation reported a 10% revenue increase in FY2025 to $61.9 million, fueled by the successful launch and commercialization of Emrosi™, a treatment for rosacea. The company improved gross margins and achieved an adjusted EBITDA of $2.9 million, signaling financial strengthening despite a net loss of $11.4 million. Emrosi™ expanded…

Colliers Completes C$550 Million Senior Notes Issuance

Colliers Completes C$550 Million Senior Notes Issuance

Colliers International Group Inc. completed a private placement of C$550 million (approx. US$400 million) in 4.73% fixed rate senior unsecured notes due 2033. The funds will be used primarily for general corporate purposes, including repayment of borrowings under their revolving credit facility, enhancing financial flexibility to support long-term …

Kratos Announces Appointment of David King to Board of Directors

Kratos Announces Appointment of David King to Board of Directors

Kratos Defense & Security Solutions has appointed David King, an experienced aerospace and defense executive, to its Board of Directors. King's extensive background includes leading Dynetics and serving as Group President at Leidos Dynetics. His expertise in defense technologies aligns with Kratos' focus areas such as unmanned systems and hypersoni…

E-Power Inc. Announces Strategic Expansion into Vietnam to Build a Resilient "Ex-China" Anode Material Supply Chain for Global AI Data Centers and ESS Markets

E-Power Inc. Announces Strategic Expansion into Vietnam to Build a Resilient "Ex-China" Anode Material Supply Chain for Global AI Data Centers and ESS Markets

E-Power Inc., listed on NASDAQ as EPOW, announced a strategic expansion into Vietnam through a partnership with ATSC SOLARTECH to establish a local production hub for anode materials targeting Artificial Intelligence Data Centers and energy storage systems. This move enhances supply chain resilience outside China, leverages tariff benefits, and sup…

Eldorado Gold Announces Leading, Independent Proxy Advisory Firm, ISS, Recommends Eldorado Shareholders Vote “FOR” the Proposed Arrangement with Foran Mining; Shareholders Reminded to Vote

Eldorado Gold Announces Leading, Independent Proxy Advisory Firm, ISS, Recommends Eldorado Shareholders Vote “FOR” the Proposed Arrangement with Foran Mining; Shareholders Reminded to Vote

Eldorado Gold Corporation announced that proxy advisory firm Institutional Shareholder Services (ISS) recommends shareholders vote in favor of the proposed arrangement to acquire Foran Mining Corporation. The transaction involves Eldorado issuing shares to Foran shareholders and aims to strengthen Eldorado's long-term growth via a value-focused mer…

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen Bio Holdings Inc. has regained compliance with Nasdaq's minimum $1.00 bid price requirement, ensuring continued listing on the Nasdaq Global Market. The company is progressing its integrated healthcare model combining immunotherapy, AI, and capital discipline, and is exploring strategic acquisitions to pivot towards a cash-flow-positive ope…

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

Denali Therapeutics announced that the U.S. FDA has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), a novel enzyme replacement therapy designed to cross the blood-brain barrier to treat neurological symptoms of Hunter syndrome (MPS II). This marks the first FDA-approved treatment targeting the brain manifestations of this rare g…

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

GH Research PLC announced the peer-reviewed publication of its Phase 2b clinical trial results for GH001 (mebufotenin) in treatment-resistant depression (TRD) in JAMA Psychiatry. The study demonstrated significant efficacy and safety of GH001, with remission rates independent of the number of prior antidepressant treatment failures, a notable break…

Enact Releases 2025 Sustainability Report

Enact Releases 2025 Sustainability Report

Enact Holdings, Inc. released its 2025 Sustainability Report detailing ongoing efforts in community engagement, employee development, governance, and risk management aligned with its mission to support sustainable homeownership. The report reflects the company’s continued focus on long-term value creation and transparency.

Vishay Intertechnology 40 LHE Linear Position Sensor Delivers High Accuracy Displacement Measurement to 40 mm in Harsh Environments

Vishay Intertechnology 40 LHE Linear Position Sensor Delivers High Accuracy Displacement Measurement to 40 mm in Harsh Environments

Vishay Intertechnology has introduced the 40 LHE linear position sensor, featuring high accuracy, extended 40 mm stroke, IP67 sealing, and robustness against vibration and shock. Designed for demanding applications across industrial automation, infrastructure monitoring, and transportation, the sensor offers immediate position reporting upon power-…